Display options
Cite
Posner H, Curiel R, Edgar C, et al. Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innov Clin Neurosci. 2017;14(1):22-29
Posner, H., Curiel, R., Edgar, C., Hendrix, S., Liu, E., Loewenstein, D. A., Morrison, G., Shinobu, L., Wesnes, K., & Harvey, P. D. (2017). Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innovations in clinical neuroscience, 14(1), 22-29.
Posner, Holly, et al. "Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs." Innovations in clinical neuroscience vol. 14,1 (2017): 22-29.
Posner H, Curiel R, Edgar C, Hendrix S, Liu E, Loewenstein DA, Morrison G, Shinobu L, Wesnes K, Harvey PD. Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innov Clin Neurosci. 2017 Feb 01;14(1):22-29. eCollection 2017. PMID: 28386518; PMCID: PMC5373792.
Copy Download .nbib Format: NLM
Share it on

Innov Clin Neurosci. 2017 Feb 01;14(1):22-29. eCollection 2017.

Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Innovations in clinical neuroscience

Holly Posner, Rosie Curiel, Chris Edgar, Suzanne Hendrix, Enchi Liu, David A Loewenstein, Glenn Morrison, Leslie Shinobu, Keith Wesnes, Philip D Harvey

Affiliations

  1. Dr. Posner is with Pfizer Inc., New York, New York; Drs. Curiel, Loewenstein, and Harvey are with the University of Miami Leonard Miller School of Medicine, Department of Psychiatry and Behavioral Sciences, Miami, Florida; Dr. Edgar is with Roche, Roche Products Ltd, Hertfordshire, United Kingdom; Dr. Hendrix is with Pentara Corporation, Salt Lake City, Utah; Dr. Liu is with Prothena Biosciences, Inc., South San Francisco, California; Dr. Morrison is with Lumos Labs, Inc., San Francisco, California; Dr. Shinobu is with Decibel, Therapeutics, Inc., Cambridge, Massachussetts; and Dr. Wesnes is with Wesnes Cognition Ltd., Streatley on Thames and Department of Psychology, Northumbria University, Newcastle, United Kingdom.

PMID: 28386518 PMCID: PMC5373792

Abstract

An evolving paradigm shift in the diagnostic conceptualization of Alzheimer's disease is reflected in its recently updated diagnostic criteria from the National Institute on Aging-Alzheimer's Association and the International Working Group. Additionally, it is reflected in the increased focus in this field on conducting prevention trials in addition to improving cognition and function in people with dementia. These developments are making key contributions towards defining new regulatory thinking around Alzheimer's disease treatment earlier in the disease continuum. As a result, the field as a whole is now concentrated on exploring the next-generation of cognitive and functional outcome measures that will support clinical trials focused on treating the slow slide into cognitive and functional impairment. With this backdrop, the International Society for CNS Clinical Trials and Methodology convened semi-annual working group meetings which began in spring of 2012 to address methodological issues in this area. This report presents the most critical issues around primary outcome assessments in Alzheimer's disease clinical trials, and summarizes the presentations, discussions, and recommendations of those meetings, within the context of the evolving landscape of Alzheimer's disease clinical trials.

Keywords: Early Alzheimer’s disease; MCI; clinical trials; cognition; functional assessment; mild cognitive impairment

Conflict of interest statement

FINANCIAL DISCLOSURES:Drs. Curiel, Harvey, Hendrix, Liu, Loewenstein, Morrison, and Shinobu have no conflicts of interest relevant to the content of this article. Dr. Edgar is an employee of Roche Pro

References

  1. Fed Regist. 1992 Dec 11;57(239):58942-60 - PubMed
  2. J Am Geriatr Soc. 1999 May;47(5):564-9 - PubMed
  3. JAMA. 1999 Aug 25;282(8):790-5 - PubMed
  4. Arch Neurol. 2004 Jan;61(1):59-66 - PubMed
  5. NeuroRx. 2004 Apr;1(2):189-95 - PubMed
  6. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593 - PubMed
  7. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154 - PubMed
  8. Lancet Neurol. 2007 Aug;6(8):734-46 - PubMed
  9. Am J Geriatr Psychiatry. 2008 May;16(5):384-8 - PubMed
  10. Alzheimers Dement. 2007 Jul;3(3):186-91 - PubMed
  11. Psychometrika. 2006 Sep;71(3):425-440 - PubMed
  12. Arch Neurol. 2010 Jun;67(6):746-9 - PubMed
  13. Alzheimers Dement. 2010 Sep;6(5):425-8 - PubMed
  14. Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7 - PubMed
  15. Lancet Neurol. 2010 Nov;9(11):1118-27 - PubMed
  16. Alzheimers Res Ther. 2011 Mar 29;3(2):11 - PubMed
  17. Alzheimers Dement. 2011 May;7(3):257-62 - PubMed
  18. Alzheimers Dement. 2011 May;7(3):280-92 - PubMed
  19. Alzheimers Dement. 2011 May;7(3):270-9 - PubMed
  20. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  21. Alzheimers Dement. 2011 Nov;7(6):602-610.e2 - PubMed
  22. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):571-85 - PubMed
  23. Neurology. 2012 May 15;78(20):1576-82 - PubMed
  24. Brain Imaging Behav. 2012 Dec;6(4):489-501 - PubMed
  25. Lancet Neurol. 2012 Aug;11(8):669-78 - PubMed
  26. N Engl J Med. 2012 Aug 30;367(9):795-804 - PubMed
  27. Alzheimers Res Ther. 2012 Jul 13;4(4):24 - PubMed
  28. Alzheimer Dis Assoc Disord. 2013 Apr-Jun;27(2):187-91 - PubMed
  29. Alzheimers Dement. 2013 Feb;9(1 Suppl):S21-31 - PubMed
  30. Brain Imaging Behav. 2012 Dec;6(4):485-8 - PubMed
  31. Alzheimers Dement. 2013 Feb;9(1 Suppl):S4-9 - PubMed
  32. Alzheimers Dement. 2013 Feb;9(1 Suppl):S10-20 - PubMed
  33. Lancet Neurol. 2013 Feb;12(2):207-16 - PubMed
  34. Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83 - PubMed
  35. N Engl J Med. 2013 Mar 28;368(13):1169-71 - PubMed
  36. PLoS One. 2013;8(3):e58816 - PubMed
  37. Acta Neurol Scand. 2014 Feb;129(2):114-22 - PubMed
  38. Lancet Neurol. 2013 Oct;12(10):957-65 - PubMed
  39. N Engl J Med. 2014 Jan 23;370(4):311-21 - PubMed
  40. N Engl J Med. 2014 Jan 23;370(4):322-33 - PubMed
  41. Neuropsychiatr Dis Treat. 2014 Jan 28;10:153-65 - PubMed
  42. J Intern Med. 2014 Mar;275(3):251-83 - PubMed
  43. N Engl J Med. 2014 Apr 10;370(15):1460 - PubMed
  44. N Engl J Med. 2014 Apr 10;370(15):1460 - PubMed
  45. Alzheimers Dement. 2014 Nov;10(6):666-74 - PubMed
  46. Lancet Neurol. 2014 Jun;13(6):614-29 - PubMed
  47. Alzheimers Res Ther. 2014 Jul 03;6(4):37 - PubMed
  48. Neurology. 2015 Aug 25;85(8):692-700 - PubMed
  49. Pharm Stat. 2015 Sep-Oct;14(5):418-26 - PubMed
  50. J Prev Alzheimers Dis. 2015 Jun;2(2):128-135 - PubMed
  51. Neurology. 2015 Oct 20;85(16):1383-91 - PubMed
  52. JAMA Neurol. 2015 Nov;72(11):1324-33 - PubMed
  53. Lancet Neurol. 2016 Apr;15(5):455-532 - PubMed
  54. J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):993-9 - PubMed
  55. Alzheimers Dement. 2016 Mar;12(3):292-323 - PubMed
  56. Innov Clin Neurosci. 2017 Feb 01;14(1-2):30-39 - PubMed
  57. Am J Psychiatry. 1984 Nov;141(11):1356-64 - PubMed
  58. Neurology. 1984 Jul;34(7):939-44 - PubMed
  59. Psychopharmacol Bull. 1983;19(3):448-50 - PubMed
  60. JAMA. 1994 Apr 6;271(13):985-91 - PubMed
  61. Neurology. 1997 Jun;48(6):1511-7 - PubMed
  62. N Engl J Med. 1998 Feb 19;338(8):506-11 - PubMed

Publication Types